In a survey last year, 100 US-based dermatologists were asked to identify how psoriasis drug brands were impacted by a series of market forces. Analysis of these survey results examined parameters such as the number of physicians prescribing each brand, how physicians choose which drugs to prescribe and the market share of competing brands. The survey found that among the eight featured brands, Humira was prescribed the most (by 96% of physicians polled), as shown in Table 1 below.
Table 1: Drug brands US physicians prescribe for psoriasis
Findings of the 2019 survey will be available in the coming weeks, and will show how prescribing patterns have changed over the past 12 months (click here to be notified when results are available). Brands featuring in the latest survey are shown in Table 2 below.
Table 2: Drug brands included in the 2019 survey on psoriasis
FirstWord has conducted similar research in 15 competitive disease areas across the US and EU. Contact us to learn more.
To read more Sponsored Story articles, click here.